Mark A Rosenthal
Overview
Explore the profile of Mark A Rosenthal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
2967
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, et al.
Asia Pac J Clin Oncol
. 2017 Oct;
14(1):84-90.
PMID: 29083093
Aim: Precision oncology involves molecularly matching patients to targeted agents usually in early drug development (EDD) programs. Molecular profiling (MP) identifies actionable targets. Comprehensive commercial MP platforms are costly and...
12.
Field K, Phal P, Fitt G, Goh C, Nowak A, Rosenthal M, et al.
Cancer
. 2017 Jul;
123(18):3576-3582.
PMID: 28678383
Background: Bevacizumab has been associated with prolonged progression-free survival for patients with recurrent glioblastoma; however, not all derive a benefit. An early indicator of efficacy or futility may allow early...
13.
Field K, King M, Simes J, Espinoza D, Barnes E, Sawkins K, et al.
J Neurooncol
. 2017 May;
133(3):623-631.
PMID: 28534153
In recurrent glioblastoma, health-related quality of life (HRQL) is a crucial trial endpoint. We examined HRQL outcomes as a secondary endpoint for patients in the CABARET randomized phase 2 trial....
14.
Bennett I, Field K, Hovens C, Moffat B, Rosenthal M, Drummond K, et al.
J Neurooncol
. 2016 Nov;
131(2):321-329.
PMID: 27896520
Bevacizumab, an anti-angiogenic agent, is FDA-approved for use in patients with recurrent glioblastoma multiforme (rGBM). The radiologic evaluation of tumor response to bevacizumab is complex and there is no validated...
15.
Parakh S, Thursfield V, Cher L, Dally M, Drummond K, Murphy M, et al.
J Clin Neurosci
. 2015 Nov;
24:78-82.
PMID: 26549675
This retrospective population-based survey examined current patterns of care for patients with recurrent glioblastoma (rGBM) who had previously undergone surgery and post-operative therapy at original diagnosis. The patients were identified...
16.
Whittle J, Lickliter J, Gan H, Scott A, Simes J, Solomon B, et al.
J Clin Neurosci
. 2015 Aug;
22(12):1889-94.
PMID: 26279503
There are limited treatment options for patients with recurrent glioblastoma (GBM). The EnGeneIC delivery vehicle (EDV) is a novel nanocellular (minicell) compound which packages theoretically effective concentrations of chemotherapeutic drugs...
17.
Connon F, Rosenthal M, Drummond K
Neurosurg Rev
. 2015 Jul;
39(1):55-60.
PMID: 26208944
Glioblastoma is the most malignant and most common primary brain tumour and is treated with resection followed by post-operative radiotherapy and chemotherapy. However, a significant amount of patients are older...
18.
Field K, Simes J, Nowak A, Cher L, Wheeler H, Hovey E, et al.
Neuro Oncol
. 2015 Jul;
17(11):1504-13.
PMID: 26130744
Background: The optimal use of bevacizumab in recurrent glioblastoma (GBM), including the choice of monotherapy or combination therapy, remains uncertain. The purpose of this study was to compare combination therapy...
19.
Gan H, Rosenthal M, Cher L, Dally M, Drummond K, Murphy M, et al.
J Clin Neurosci
. 2015 Jun;
22(9):1462-6.
PMID: 26117358
We describe the management of patients with newly diagnosed glioblastoma multiforme (GBM) in a population-based cohort and compare this to a previously studied cohort. We performed a retrospective cohort study...
20.
Asaid M, Preece P, Rosenthal M, Drummond K
J Clin Neurosci
. 2015 Jun;
22(9):1392-6.
PMID: 26094561
This study reviews our tertiary hospital experience in an adult population of ependymoma patients. Ependymomas are uncommon tumours of the central nervous system (CNS) and the literature provides little information...